- Company has signed an agreement with Thermo Fisher Scientific to extend their cardiology products distribution relationship by two years through December 2010.
- The co-exclusive agreement continues to cover all of the cardiology and drugs of abuse rapid test products manufactured by the Biosite subsidiary of Inverness and sold under the Triage brand including tests for BNP, troponin, CK-MB, Myoglobin, d-dimer and a broad range of meter and visually read drugs of abuse tests.

Other headlines for [IMA]

• IMA 11/4/2008 08:15am
  Inverness Medical Innovations Inc Signs distribution agreement with PrognostiX for CardioMPO Test- The CardioMPO Test, the only FDA-cleared diagnostic of its kind, measures myeloperoxidase, or MPO, an enzyme found in the blood. An more...
  
• IMA 10/30/2008 07:28am
  Inverness Medical Innovations Inc Price Target lowered to $35 from $43 at Merrill, maintains buy rating
  
• IMA 10/29/2008 08:02am
  Inverness Medical Innovations Inc Reports Q3 $0.46 v $0.50e (ex items), R $438.8M v $438.6Me
  
• IMA 10/14/2008 06:59am
  Inverness Medical Innovations Inc Lazard Initiates IMA with Buy, price target: $42
  

Healthcare sector headlines

• CUR Today 08:02am
  Neuralstem Inc Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials- The collaboration will focus on Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with Dr. more...
  
• SVA Today 08:01am
  Sinovac Biotech Announces share buyback of up to $2M (5.5% of market cap)
  
• PRX Today 08:01am
  Par Pharmaceutical Companies Inc. Announces successful completion of Bioequivalence Studies for Ondansetron Thin Film- The ondansetron thin film product is being developed for the prevention of chemotherapy-induced nausea and more...
  
• CSKI Today 08:01am
  China Sky One Medical, Inc. Names Yu-Bo Hao new CFO- He replaces Yu-kun Zhang, who had served as interim CFO since June, 2008. - Mr. Hao has been employed at China Sky One in various capacities since June, 2008. - From more...
  
• THRX Today 08:01am
  Theravance Inc Announces positive Phase 2b results for LABA, '444 in the Horizon Asthma Development Programme with GSK- The study, which was designed to evaluate the efficacy of five doses of '444 administered more...